Inventor profile of:

Brian Seed

City:

Boston, Massachusetts

Country:

United States

Published Applications:

46

Last publication date:

2025-09-18

Top Assignees for applications by Brian Seed

The entities that hold a legal rights for patent applications filed by inventor Seed Brian:

Recent patent applications by Seed Brian

Brian Seed from Boston, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-09-18
US20250288648A1
Human necessities

INTERFERON FOR THE TREATMENT OF BRACHYURY-ASSOCIATED CANCERS AND NEOPLASMS

#2 | 2025-07-31
US20250241888A1
Human necessities

COMPOUND FOR THE MANAGEMENT OF FELINE DIABETES

#3 | 2024-05-02
US20240139109A1
Human necessities

PHARMACEUTICAL FORMULATIONS

#4 | 2024-01-25
US20240024279A1
Human necessities

METHODS FOR REDUCING THE WEIGHT LOSS OR INCREASING THE WEIGHT OF A FELINE IN NEED THEREOF

#5 | 2023-11-23
US20230372374A1
Human necessities

VETERINARY PHARMACEUTICAL FORMULATIONS

#6 | 2023-09-28
US20230303709A1
Chemistry; metallurgy

Antibody Derivatives with Conditionally Enabled Effector Function

#7 | 2023-01-05
US20230000816A1
Human necessities

SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS

#8 | 2022-04-21
US20220117898A1
Human necessities

PHARMACEUTICAL FORMULATIONS

#9 | 2020-11-12
US20200352968A1
Human necessities

METHODS FOR REDUCING THE WEIGHT LOSS OR INCREASING THE WEIGHT OF A FELINE IN NEED THEREOF

#10 | 2020-09-17
US20200289457A1
Human necessities

Compound for the management of feline diabetes

#11 | 2020-07-30
US20200239510A1
Chemistry; metallurgy

Crystalline form of benzylbenzene SGLT2 inhibitor

#12 | 2019-11-14
US20190343853A1
Human necessities

METHODS OF TREATING HYPERTENSION

#13 | 2018-08-02
US20180215831A1
Chemistry; metallurgy

Antibody derivatives with conditionally enabled effector function

#14 | 2018-05-03
US20180118773A1
Chemistry; metallurgy

Crystalline form of benzylbenzene SGLT2 inhibitor

#15 | 2016-07-21
US20160207952A1
Chemistry; metallurgy

Process for the preparation of benzylbenzene SGLT2 inhibitors

#16 | 2015-09-24
US20150266915A1
Chemistry; metallurgy

Crystalline form of benzylbenzene SGLT2 inhibitor

#17 | 2014-04-24
US20140113832A1
Chemistry; metallurgy

Engineered thioredoxin-like fold proteins

#18 | 2014-01-30
US20140031300A1
Chemistry; metallurgy

Benzylbenzene derivatives and methods of use

#19 | 2014-01-09
US20140011754A9
Chemistry; metallurgy

Crystalline form of benzylbenzene SGLT2 inhibitor

#20 | 2013-10-10
US20130267694A1
Chemistry; metallurgy

Process for the preparation of benzylbenzene SGLT2 inhibitors

#21 | 2012-12-27
US20120329732A1
Chemistry; metallurgy

Benzylbenzene derivatives and methods of use

#22 | 2012-09-20
US20120238510A1
Chemistry; metallurgy

CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR

#23 | 2011-12-22
US20110312946A1
Human necessities

Combination therapy for the treatment of diabetes

#24 | 2011-08-25
US20110207661A1
Chemistry; metallurgy

Benzylbenzene derivatives and methods of use

#25 | 2011-08-11
US20110195952A1
Human necessities

Treating psychological conditions using muscarinic receptor Mantagonists

#26 | 2011-03-31
US20110077212A1
Human necessities

THERAPEUTIC USES OF SGLT2 INHIBITORS

#27 | 2011-03-10
US20110059504A1
Chemistry; metallurgy

Engineered transglutaminase barrel proteins

#28 | 2011-01-27
US20110021507A1
Human necessities

INHIBITING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN

#29 | 2010-10-07
US20100256070A1
Chemistry; metallurgy

Fusion proteins comprising a fragment of exotoxin A

#30 | 2010-08-26
US20100215677A1
Physics

PDZ DOMAIN INTERACTIONS AND LIPID RAFTS

#31 | 2010-03-11
US20100063141A1
Human necessities

Deuterated benzylbenzene derivatives and methods of use

#32 | 2010-03-04
US20100055761A1
Chemistry; metallurgy

Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting

#33 | 2009-05-07
US20090118201A1
Chemistry; metallurgy

Benzylbenzene derivatives and methods of use

#34 | 2008-07-15
US8756018
-

Nucleic acids encoding artificial P-selectin ligands

#35 | 2008-07-10
US20080166736A1
Physics

PDZ DOMAIN INTERACTIONS AND LIPID RAFTS

#36 | 2008-01-22
US10151193
-

Redirection of cellular immunity by protein tyrosine kinase chimeras

#37 | 2007-12-20
US20070293481A1
Human necessities

Treating obesity with muscarinic receptor Mantagonists

#38 | 2007-12-20
US20070293480A1
Human necessities

Treating psychological conditions using muscarinic receptor Mantagonists

#39 | 2007-08-07
US8293603
-

Immunoglobulin fusion proteins, their production and use

#40 | 2006-10-10
US9836544
-

Rapid immunoselection cloning method

#41 | 2006-09-19
US9735024
-

Methods and compositions for the rapid and enduring relief of inadequate myocardial function

#42 | 2006-08-22
US9939537
-

Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells

#43 | 2006-05-23
US9243008
-

Redirection of cellular immunity by receptor chimeras

#44 | 2006-04-27
US20060088898A1
Chemistry; metallurgy

Methods for the production of cells and mammals with desired genetic modifications

#45 | 2005-06-30
US20050142609A1
Chemistry; metallurgy

Native immunoglobulin binding reagents and methods for making and using same

#46 | 2005-03-24
US20050063979A1
Human necessities

Antigen presenting vesicles

InventorID:

478560 ⎘